Table 3.

Diseases of the basal ganglia and cerebellum outcomes in non-ADHD subjects and ADHD patients

	Matched non-ADHD subjects							ADHD patients
	Total	BG&C		BG&C <50  y		PD		Total	BG&C		BG&C <50 y		PD
	N	N	Row%	N	Row%	N	Row%	N	N	Row%	N	Row%	N	Row%
All subjects	158,790	297	0.19	181	0.11	96	0.06	31,769	166	0.52	111	0.35	56	0.18
Sex
Females	67,802	154	0.23	91	0.13	42	0.06	13,564	84	0.62	56	0.41	31	0.23
Males	90,988	143	0.16	90	0.10	54	0.06	18,205	82	0.45	55	0.30	25	0.14
ADHD treatmenta
+stimulants	24,792	56	0.23	26	0.10	19	0.08	4960	62	1.25	42	0.85	19	0.38
None/unknown	133,998	241	0.18	155	0.12	77	0.06	26,809	104	0.39	69	0.26	38	0.14

	Median (r)	Mean (±s.d.)	Median (r)	Mean (±s.d.)
BG&C index age (y)	45 (21–66)	44.2 (12.0)	43 (21–66)	42.7 (11.5)
Y to BG&C onset	5 (<1–19)	5.4 (5.0)	6 (<1–19)	6.6 (5.0)

BG&C diseases of the basal ganglia and cerebellum, y years, <50 y BG&C onset at ages 21–49 years, PD Parkinson’s disease (ICD-9 332.0)

^a For the non-ADHD cohort, subjects were matched to their respective ADHD patients